Sharp Therapeutics Corp. operates as a biology technology company. It focuses on compounds that improve the function of mutated proteins and enhance the activity of the remaining un-mutated protein copy in haploinsufficiency. The company has developed the CoreX biology, AlloChem chemistry and Disco computational technologies to discover small molecules that restore activity in mutated proteins, or that increase activity in the normal copy of the gene in the case where an only single unmutated gene remains. The firm applies these technologies across a portfolio of diseases of high unmet medical need. The company was founded on December 12, 2024 and is headquartered in Pittsburgh, PA.